RCKT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RCKT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Rocket Pharmaceuticals does not have enough data to calculate Degree of Operating Leverage.
The historical data trend for Rocket Pharmaceuticals's Degree of Operating Leverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rocket Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Degree of Operating Leverage | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Rocket Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Degree of Operating Leverage | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Rocket Pharmaceuticals's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's Degree of Operating Leverage distribution charts can be found below:
* The bar in red indicates where Rocket Pharmaceuticals's Degree of Operating Leverage falls into.
Rocket Pharmaceuticals's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:
Degree of Operating Leverage | = | % Change in EBIT** | / | % Change in Revenue |
= | ( -256.139 (Mar. 2025) / -247.436 (Mar. 2024) - 1 ) | / | ( 0 (Mar. 2025) / 0 (Mar. 2024) - 1 ) | |
= | 0.0352 | / | ||
= | N/A*** |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Rocket Pharmaceuticals (NAS:RCKT) Degree of Operating Leverage Explanation
Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.
A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.
Be Aware
The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.
Thank you for viewing the detailed overview of Rocket Pharmaceuticals's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Martin Wilson | officer: General Counsel | C/O TELIGENT, INC., 105 LINCOLN AVENUE, BUENA NJ 08310 |
Jonathan David Schwartz | officer: Chief Medical Officer | 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016 |
Gaurav Shah | director, officer: See Remarks | 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016 |
John Militello | officer: See Remarks | C/O IMMUNE PHARMACEUTICALS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016 |
Kinnari Patel | officer: Chief Operating Officer | 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016 |
Mark Andrew White | officer: Chief Medical Officer | C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY NJ 08512 |
David P Southwell | director, officer: See Remarks | C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421 |
Gotham Makker | director | 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016 |
Rtw Investments, Lp | 10 percent owner | 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
Fady Ibraham Malik | director | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Carlos Garcia-parada | officer: Chief Financial Officer | C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE SUITE 7530, NEW YORK NY 10118 |
Elisabeth Bjork | director | C/O ROCKET PHARMACEUTICALS, INC., 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10116 |
Kamran Alam | officer: SVP - Finance & PFO | 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118 |
Naveen Yalamanchi | director | 412 WEST 15TH STREET, 9TH FLOOR, NEW YORK NY 10019 |
Brian Batchelder | officer: See Remarks | 430 EAST 29TH STREET, SUITE 1040, NEW YORK NY 10016 |
From GuruFocus
By GuruFocus News • 05-28-2025
By GuruFocus News • 05-27-2025
By GuruFocus News • 05-28-2025
By GuruFocus News • 05-16-2025
By GuruFocus News • 05-28-2025
By GuruFocus News • 05-27-2025
By GuruFocus News • 05-28-2025
By GuruFocus News • 05-27-2025
By Marketwired • 05-28-2025
By GuruFocus News • 05-27-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.